The physiological role of IGF-II remains unclear but there is evidence for a role in postnatal growth, the growth of the thymus and bone homeostasis. Glucocorticoids have many effects that are opposite to the effects of IGF-II such as growth retardation, osteoporosis and thymic involution. We therefore wondered whether IGF-II overexpression in transgenic mice might counteract some of the growth inhibitory effects of the glucocorticoid, dexamethasone (DXM).
Introduction
The insulin-like growth factor (IGF)-I is an important regulator of growth. The physiological role of the structurally related peptide IGF-II, however, remains unclear (Gluckman & Ambler 1993 , van Buul-Offers 1996 , Wolf et al. 1998 .
Studies on the role of IGF-II in postnatal growth have given conflicting results. In hypophysectomized rats IGF-II administration promotes growth although less well than IGF-I (Schoenle et al. 1985 , Shaar et al. 1989 , Conlon et al. 1995 . Similar results were obtained in Pit-1-deficient Snell dwarf mice (van Buul-Offers et al. 1988 . In contrast, IGF-II was ineffective when administered to hypophysectomized neonatal rats (Glasscock et al. 1992) , and treatment of neonatal rats with IGF-II antibodies did not change body weight (Robinson et al. 1993) . Furthermore, overexpression of IGF-II in transgenic normal and dwarf mice did not affect overall body growth (Rogler et al. 1994 , Ward et al. 1994 , van Buul-Offers et al. 1995 , Wolf et al. 1995 and mice bearing IGF-IIproducing tumors did not show increased body growth (Wilson et al. 1987 , Ren-Qiu et al. 1993 .
There are some indications for a role of IGF-II in the thymus. IGF-II is present in the thymus (Geenen 1993) and transgenic overexpression of IGF-II mRNA and protein in the medulla of the thymus induced thymic overgrowth (van Buul-Offers et al. 1995 , Van Der Ven et al. 1997 .
IGF-II may also be a regulator of bone homeostasis. IGF-II is identical to skeletal growth factor (Mohan et al. 1988) and is present in large quantities in bone (Frolik et al. 1988) . IGF-II/skeletal growth factor is produced by and is mitogenic for osteoblasts (Wergedal et al. 1990 , Mohan & Baylink 1996 . In addition it is the dominant IGF expressed in the growth plate of immature and growing rats (Shinar et al. 1993 , Wang et al. 1995 and mice (Wang et al. 1995) .
Glucocorticoids have many effects that are opposite to the effects of IGF-II. They are growth suppressing in many species including mice (Silbermann et al. 1976) , rats (Simmons & Kunin 1967 , Ortoft et al. 1998 ) and man (Allen et al. 1994) and cause osteoporosis (Orwoll & Klein 1995) . Furthermore they induce involution of the thymus (Franco et al. 1990 , Ortoft et al. 1998 .
Therefore, we wondered whether IGF-II-transgenic mice are more resistant to the effects of glucocorticoids than their normal controls with respect to growth of the total body, various organs and selected bones.
Materials and Methods

Animals
Transgenic (Tg) mice expressing human IGF-II under the control of the H2Kb promotor (Tg II mice) were generated as described in detail previously (van Buul-Offers et al. 1995) . For these experiments mouse line 74 was used which carries about 100 copies of a mini-gene containing 178 base pairs of exon 5 and exons 7, 8 and 9. As controls, the background strain of the transgenic mice (strain FVB) was used.
The animals were bred and kept under standardized conditions as described previously (van Buul-Offers et al. 1995) .
Experimental design
Experiment 1 Three-week-old female FVB mice were divided into 4 groups of 5 animals.The mice were selected to ensure equal means and standard deviations for length and weight in each group at the start of the experiment. The animals were injected once a day subcutaneously with 0·1 ml vehicle (phosphate-buffered saline (PBS), pH 7·4) or 0·2 µg, 2 µg or 20 µg dexamethasone (DXM) per animal per day, 5 days a week for a total time of 4 weeks.
The animals were measured and weighed every week. Snout-tail length was determined under ether anesthesia by the method of Hughes and Tanner (1970) . The mice were killed by cervical dislocation under ether anesthesia 2 h after the last injection. Organs were immediately removed, frozen in liquid nitrogen and weighed to the nearest milligram. The tibiae were carefully dissected out and cleared from adjacent muscle. The length of the tibia was determined on frozen bones using a caliper calibrated to 0·05 mm. The lumbar vertebrae were dissected out and the surrounding soft tissue was removed as much as possible. To further minimize the contribution of muscle tissue to the weight, the vertebrae were immersed in ethanol:ether (1:1) and dried prior to weighing. Experiment 2 Female FVB and Tg II mice (3 weeks old) were divided into 2 groups of 5 mice each. The animals were injected subcutaneously with 0·1 ml vehicle or 20 µg DXM per animal once a day, 5 days a week for a total time of 4 weeks. Body and organ parameters were determined as described in experiment 1.
Growth plate histomorphometry
Tibiae were broken near the middle of the diaphysis, decalcified for 24 h in 0·5 M phosphate-buffered EDTA, pH 8·0, fixed in 3·8% formalin and embedded in paraffin in a standardized way to ensure proper orientation. Frontal sections (10 µm) were cut from ventral to dorsal and proximal to distal. The center of the growth plate was determined as described previously (Smeets & van Buul-Offers 1983a,b) . For each animal, 3 sections situated at the center were stained with a pentachrome stain according to Movat (1955) . Histomorphometry was performed using the Image software program on a Macintosh computer. The boundary between the resting zone and the proliferating zone of the growth plate was traced by hand and approximated by a fifth degree polynomial. A similar procedure was carried out on the boundary between the proliferating and the hypertropic zone and between the hypertropic zone and the bone marrow. The Image program then calculates the mean distance between the three polynomes.
Determination of serum IGF-I and IGF-II
Serum IGF-I and IGF-II concentrations were determined as described before (van Buul-Offers et al. 1994) . Briefly, mouse serum was treated with acid and separated over C-18 cartridges (SepPak, Waters Associates, Milford, MA, USA). IGF-I and IGF-II were measured by a heterologous radioimmunoassay using the anti-human IGF-I rabbit antiserum kindly provided by Dr P Gluckman, Auckland, New Zealand and an anti-rat-IGF-II monoclonal antibody (Amano Pharmaceuticals Co. Ltd, Osaka, Japan) respectively.
Western ligand blot for IGF binding proteins (IGFBPs)
Serum IGFBPs were analyzed by polyacrylamide gel electrophoresis and Western ligand blotting according to Hossenlopp et al. (1986) as described previously (van Buul-Offers et al. 1994) . Blots were pretreated with 3% Nonidet P-40 (BDH Laboratory, Poole, Dorset, UK) (30 min), 1% BSA (60 min) and 0·1% Tween 20 (5 min) in TBS buffer (10 mM Tris-HCl, 150 mM NaCl, pH 7·4), incubated with human 125 I-IGF-II (2 10 6 c.p.m./ blot in 25 ml TBS containing 1% BSA and 1% Tween-20 for 4 h at room temperature) and washed in TBS (2 15 min). The blotted IGFBPs were visualized by autoradiography on Fuji RX film or on a phospho-imager screen and quantified with the Molecular Imager (BioRad, Hercules, CA, USA).
Statistical analysis
The differences between groups were analyzed by Scheffé's test if multiple doses were compared. For comparison of two groups, a two-tailed Student's t-test was used.
Results
Dose-effect relationship of dexamethasone in normal (FVB) mice
Effects on body length, body weight, tibia, humerus and lumbar vertebrae Different doses of DXM were tested in normal mice in order to find a dose that inhibited growth without causing starvation or death.
The increment in length during the 4 weeks of the experiment is shown in Fig. 1 . DXM inhibited growth dose dependently. The growth reduction was signifcant at a dose of 2 and 20 µg/day.
Body weight decreased in parallel to body length. Consequently, weight-for-length remained constant except at the highest dose of DXM when it decreased by 10% (Table 1) .
In contrast to body length, tibia length was only slightly affected by DXM. Therefore the width of the growth plate was determined histomorphometrically in the PBS and the DXM 20 µg/day groups at the end of the experiment. The total width of the growth plate slightly diminished in the DXM-treated animals mainly due to a decrease in the width of the proliferative layer. The hypertropic zone remained unaffected (Table 1) .
The weight of the tibia, humerus and lumbar vertebrae decreased dose-dependently following administration of DXM but the decrease was only statistically significant for the lumbar vertebrae (Table 1) .
Effects on various organs
For all organs studied, a dose-dependent decrease in weight was obtained. However, the various organs have a different sensitivity towards the growth inhibitory effect of DXM.
Kidney weight decreased in proportion to body weight, while liver and muscle weight were proportionally more affected (Table 1) . Moreover, the highest dose of DXM dramatically decreased the weight of the thymus to about 30% of vehicle-treated animals. Spleen weight was already decreased by 2 µg/day and was reduced to about 40% at the highest DXM dose. Table 2 summarizes the body and organ parameters of normal and IGF-II-transgenic animals. Overexpression of IGF-II did not modify body length or body weight as reported previously (van Buul-Offers et al. 1995) . Consequently, weight-for-length was identical in the vehicletreated FVB and transgenic mice (1·21 0·03 g/cm vs 1·21 0·03 g/cm). There was a tendency towards lower weights for tibia, humerus and lumbar vertebrae in the transgenic mice but the difference did not reach statistical significance. Transgenic animals also showed a significant increase in the weight of the spleen and thymus as described previously (van Buul-Offers et al. 1995) .
Body and organ size in normal and transgenic animals
Effect of dexamethasone in normal and IGF-II-transgenic mice
Based on the results of experiment 1, a dose of 20 µg DXM was chosen to compare its effects in normal and Tg mice.
Effect on body length and weight
The increment in body length of both types of mice during the treatment period is shown in Fig. 2 . Dexamethasone 20 µg/day decreased the growth velocity from 4·2 cm/4 weeks to 3·3 cm /4 weeks (78%) in the normal mice. In the transgenic animals it decreased from 4·3 cm/4 weeks to 3·4 cm/4 weeks (81%). Although the body length of Tg II mice tended to be less affected by DXM, the difference did not reach statistical significance.
In contrast, transgenic animals lost more weight when treated with DXM than FVB mice. Their weight-forlength was 1·04 0·02 g/cm vs 1·12 0·02 g/cm in the FVB mice (P<0·05, Student's t-test) at the end of treatment.
Effect on individual bones
The effect of DXM on tibia, humerus and lumbar vertebrae is shown in Fig. 3 . The length of the tibia decreased in the FVB but not in the Tg II mice. Likewise, tibia weight decreased following DXM in the FVB mice but not in the Tg II mice (13·4% 1·1% vs 1·5% 3·4%, P<0·05). Consequently, tibia weight-forlength was decreased by DXM in the FVB mice (from 2·87 0·1 to 2·61 0·03 mg/mm) but not in the transgenic animals (from 2·73 0·03 to 2·75 0·1 mg/mm).
The results for the humerus were similar to the results for the tibia. The weight of the humerus decreased much more following DXM in the FVB animals than in the transgenic mice. Humerus weight-for-length significantly decreased in the normal mice from 2·76 0·05 mg/mm to 2·36 0·04 (Pc0·01 Student's t-test). In the transgenic animals humerus weight-for-length decreased slightly from 2·56 0·05 to 2·42 0·02 (not significant, Student's t-test).
In contrast, this sparing effect was not seen in the lumbar vertebrae. DXM decreased lumbar vertebrae weight equally in both strains of mice.
Effect on organ weight
The weights of the kidney, liver, spleen and M. quadriceps femoris decreased following DXM administration in a similar manner in both mice strains (Fig. 4) .
Thymus weight was higher in the non-treated transgenic animals than in the FVB mice. Dexamethasone decreased the weight of the thymus more in the transgenic than in the control animals (43% vs 29%; P<0·05, Student's t-test). 
IGF-I, IGF-II and IGFBPs in serum
Serum IGF-I and IGF-II concentrations in the different treatment groups are shown in Table 3 . The levels of IGF-I were somewhat higher in the transgenic mice. Dexamethasone increased the levels of IGF-I in normal mice but not in transgenic mice. The IGF-II levels in the Tg II mice were more than 40-fold higher than in normal mice. Dexamethasone significantly decreased the IGF-II levels but they still remained more than 20-fold higher than in the normal mice. The IGFBPs were analyzed by Western ligand blotting using radiolabeled IGF-II (Fig. 5) . The sera of both mice strains showed the expected bands at 41·5 kDa (most probably the IGFBP-3 doublet), 30 kDa, 28·5 kDa, 26·5 kDa and 24 kDa (probably IGFBP-4). In normal mice, DXM only affected the 24 kDa band which was significantly decreased. In transgenic mice, all IGFBPs were increased (significantly higher levels for the bands situated at 41·5 kDa, 30 kDa, and 26·5 kDa). In these animals, DXM reduced the 24 kDa, 26·5 kDa and 38·5 kDa bands.
Discussion
Glucocorticoids exert a profound catabolic effect on experimental animals and in man. To date, growth 
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hormone (GH) and IGF-I were used to counteract these undesirable effects but the results of these studies have been a partial response at best (Laron et al. 1963 , Altman et al. 1992 , Rivkees et al. 1994 , Ortoft et al. 1998 . IGF-II has some biological effects that may counteract the catabolic effects of glucocorticoids but, to the best of our knowledge, has never been tried in this situation before.
First, we determined a dose for DXM that would inhibit growth but would still allow the animals to gain weight. Therefore, in the first experiment we administered three different doses of DXM to normal mice. Longitudinal growth was already inhibited at 2 µg/day and was one of the most sensitive parameters. At the growth plate level we found a slight decrease in total growth plate width in DXM-treated animals. This was due to a significant reduction in the proliferative zone in the steroid-treated mice. This is in line with data from Silbermann and Kadar (1977) who reported a small decrease in total width which was totally accounted for by the significant decrease in the width of the proliferative layer. In a similar experimental design, Altman et al. (1992) found a significant decrease in total growth plate width. Their strain of mice was, however, different from ours since they reported a total growth plate width that is 2·5 times as large as our measurements.
The various body parts of normal mice have a different susceptibility to the inhibiting effects of DXM. Tibia, humerus and lumbar vertebrae weight decreased less than total body weight. Liver, kidney and skeletal muscle paralleled total body weight. The lymphoid organs, thymus and spleen, were most vulnerable to glucocorticoid administration. The deleterious effect of glucocorticoids on the thymus was also reported in rats and is probably caused by an increased rate of apoptosis of the thymocytes (Zucker et al. 1994) .
Since IGF-II and glucocorticoids have several antagonistic actions on body growth, lymphoid organs and bone, the effect of DXM was studied in animals that have high circulating levels of IGF-II. Increased levels of IGF-II were obtained by creating transgenic mice in which the human IGF-II gene was placed under the control of the H2Kb promoter. In this model, the expression of the transgene is ubiquitous with very high expression in spleen and thymus (van Buul-Offers et al. 1995 , Van Der Ven et al. 1997 . In addition to the high expression of IGF-II in various organs, the serum levels for IGF-II were increased 40-fold. Therefore, in this model, the overstimulation by IGF-II occurs at the endocrine and the paracrine/ autocrine level.
Western ligand blot analysis of the serum of transgenic animals showed an increase of the binding proteins of the 41·5 kDa band (most probably an IGFBP-3 species), 30 kDa and 26·5 kDa (probably a glycosylated form of IGFBP-4). In other IGF-II-transgenic mouse models increased levels of IGFBP-2 (Rogler et al. 1994 , Wolf et al. 1994 , IGFBP-1 and IGFBP-5 have been noted (Rogler et al. 1994) . A drop in the serum level of IGF-I has often been observed after IGF-II administration or IGF-II overproduction (Douglas et al. 1991 , Koea et al. 1992 , Rogler et al. 1994 , Conlon et al. 1995 , Wolf et al. 1995 . The reduction in serum IGF-I is most likely due to displacement of IGF-I from the binding proteins in the presence of high concentrations of IGF-II (Blackburn et al. 1997) . In these models the concomitant decrease in IGF-I may have masked some biological effects of IGF-II. In our transgenic mice, IGF-I levels were unchanged. We speculate that the induction of several binding proteins has increased the binding capacity of the transgenic mouse serum and therefore prevented displacement of IGF-I.
IGF-II-transgenic and normal mice were simultaneously treated with 20 µg DXM per animal per day. This dose of DXM was chosen since it caused a significant growth retardation without starvation. In several reports on the effect of glucocorticoids in rodents, doses were used that induced a significant loss of weight (Simmons & Kunin 1967 , Lo et al. 1996 . In this study, the mice kept gaining weight and the weight-forlength ratio decreased by only 10%.
IGF-II overexpression did not affect longitudinal growth in this model as described previously (van Buul-Offers et al. 1995) nor did it change the length of the tibia and the humerus. The role of IGF-II in postnatal longitudinal growth, therefore, appears to be limited. The physiological meaning of the high levels of IGF-II in the growth plate when studied by in situ hybridization analysis (Shinar et al. 1993 , Wang et al. 1995 remains unclear.
The inhibition of longitudinal growth caused by DXM was not prevented by overexpression of IGF-II.
Transgenic animals lost slightly more weight under DXM treatment than FVB mice. This increased weight loss is not reflected in any of the organs studied. During the dissection of the animals we noticed little subcutaneous fat in the DXM-treated transgenic animals. We speculate, therefore, that the Tg II mice have an increased susceptibility to the lipolytic effect of DXM. Reduced fat mass has been reported in other IGF-II-transgenic mice (Rogler et al. 1994 , Ward et al. 1994 .
IGF-II mRNA and protein are highly expressed in lymphoid tissues such as the thymus and the spleen and cause overgrowth of the thymus in IGF-II-transgenic mice (van Buul-Offers et al. 1995 , Van Der Ven et al. 1997 . The increase in size of the thymus in the transgenic animals is predominantly due to an increase in cortical thickness with elevated numbers of T lymphocytes (Kooijman et al. 1995) . Despite the high concentrations of IGF-II in these lymphoid organs, no protective effect of IGF-II was found against the DXM-induced involution of the thymus and spleen. We have excluded the possibility that DXM had switched-off the transgene expression in thymus and spleen since there was no difference in signal intensity for IGF-II measured by in situ hybridization or immunohistochemistry between controls and DXMtreated transgenic mice (data not shown).
Dexamethasone caused equal growth inhibition of liver, kidneys and muscle in control and transgenic mice. A different picture was seen in the skeleton. The weight of the tibia and the humerus was better maintained in the DXM-treated transgenic animals. There are several hypotheses to explain this observation. The first explanation may lie in the choice of the H2Kb promoter to drive the transgene. The H2Kb gene is highly expressed in bone marrow cells that lie in close proximity to the bone trabeculae (Koster JG personal communication). Transgenically made IGF-II may, therefore, be locally present in large amounts and stimulate bone formation. Indeed, IGF-II is identical to skeletal growth factor (Mohan et al. 1988) and is present in large quantities in bone (Frolik et al. 1988) . IGF-II/skeletal growth factor is produced by and is mitogenic for osteoblasts (Wergedal et al. 1990 , Mohan & Baylink 1996 . There are, of course, many alternative explanations e.g. glucocorticoids may enhance the effect of IGF-II in a tissue-specific manner e.g. by inducing components of the IGF-II signal transducing system in osteoblasts. Since we did not separate the bone marrow from the bones, the increased weight of tibia and humerus may be due to an increase in the weight of the bone marrow. It is unclear why IGF-II did not preserve the lumbar vertebrae weight in the DXM-treated transgenic animals.
IGF-I serum concentrations were not decreased in DXM-treated mice, which is in line with data reported in normal rats (Luo & Murphy 1989 , Ortoft et al. 1998 .
The serum levels of IGF-II in the DXM-treated transgenic animals decreased by 35%. Different explanations can be offered. First, direct effects of glucocorticoids on IGF-II gene expression have been reported (Li et al. 1998) . In our animals IGF-II transgene expression was not altered in the thymus, spleen and bone marrow (data not shown). Secondly, IGF-II is highly expressed in the thymus, the spleen and the bone marrow of these transgenic mice. Dexamethasone did not affect the level of IGF-II mRNA expression per cell but it dramatically decreased the number of cells in these organs. Lastly, DXM decreased the levels of some binding protein proteins which may function as an important reservoir for IGF-II in the serum.
Indeed, in Tg II mice DXM lowered the intensity of the binding protein bands on Western ligand blots at 38·5 kDa (IGFBP-3), 26·5 kDa and 24 kDa (probably IGFBP-4). In the normal mice we only noticed an effect on the 24 kDa species. In the literature, there are no data available for the effect of glucocorticoids on IGFBPs in mice. In rats, however, DXM was reported to increase the synthesis of IGFBP-1 and IGFBP-3 (Luo & Murphy 1990 , Rodgers et al. 1995 and decrease the levels of IGFBP-2 and IGFBP-4 (Rodgers et al. 1995) . Our results do not support a significant effect of DXM on IGFBP-3 but do confirm the reduction of IGFBP-4 (24 kDa band) in mice.
Our results do not explain the mechanism of growth inhibition by glucocorticoids but refute some hypotheses offered by others, at least in mice. Since GH and IGF-I have important effects on longitudinal growth, many investigators have looked for an interference by glucocorticoids with the GH-IGF-growth plate system. Interactions of glucocorticoids with almost every step of this pathway have been published such as the inhibition of growth hormone secretion (Giustina & Wehrenberg 1992) , down-regulation of the growth hormone receptor (King & Carter-Su 1995) , the induction of circulating inhibitors of IGF action (Unterman & Phillips 1985) , modulation of IGFBPs (Miell et al. 1994) , the inhibition of IGF-I synthesis (Luo & Murphy 1989) , down-regulation of the type I IGF receptors (Robinson et al. 1993) or interference with post receptor events (Klaus et al. 1996) .
Since serum IGF-I levels did not decrease after 4 weeks of DXM administration, interference with GH secretion or IGF-I synthesis is unlikely. Our data also fail to support the hypothesis that glucocorticoids significantly increase the IGFBPs and therefore decrease the bioavailability of the IGFs. We cannot rule out or prove an effect of glucocorticoids on IGF bioactivity or on the induction of inhibitors of IGF action.
In conclusion, this study indicates that overproduction of IGF-II by a transgenic approach does not prevent glucocorticoid-induced inhibition of growth. Of all the body parts tested only tibia and humerus were partly protected against the catabolic effect of glucocorticoids. Further experiments are needed to determine how IGF-II and glucocorticoids interact in bone metabolism.
